<DOC>
	<DOCNO>NCT03041012</DOCNO>
	<brief_summary>To evaluate effect early viral reactivation latency reverse agent ( LRA ) and/or administration potent broadly neutralizing antibody ( bNAb ) size latent HIV-1 reservoir treatment naïve HIV-1 patient initiate antiretroviral therapy ( ART )</brief_summary>
	<brief_title>Early Administration Romidepsin 3BNC117 Treatment-naïve HIV Patients Starting ART</brief_title>
	<detailed_description>The study conduct among ART naïve HIV-1-infected patient . Subjects continue ART receive LRA romidepsin and/or bNAb 3BNC117 .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Documented HIV1 infection CD4+ T cell count &gt; 200/µL last visit prior study entry ART naïve Able give inform consent Any significant acute medical illness ( include primary HIV infection ) past 8 week Any evidence active AIDSdefining opportunistic infection Active alcohol substance use , Investigator 's opinion , prevent adequate compliance study therapy The following laboratory value screen , value repeat within screen period , test result must available baseline ( day 0 ) check eligibility : Hepatic transaminase ( AST ALT ) ≥3 x upper limit normal ( ULN ) Serum total bilirubin ≥3 ULN Estimated glomerular filtration rate ( eGFR ) ≤60 mL/min ( base serum creatinine appropriate validate marker ) Platelet count ≤100 x10^9/L Absolute neutrophil count ≤1x10^9/L Serum potassium , magnesium , phosphorus outside ≥1.5 ULN/LLN Total calcium ( correct serum albumin ) ionize calcium ≥1.5 ULN/LLN Hepatitis B C infection indicate presence hepatitis B surface antigen ( HBsAg ) hepatitis C virus RNA ( HCVRNA ) blood ECG screening show QTc &gt; 450 m calculate use Fridericia formula either lead V3 V4 [ 86 ] Use : Warfarin warfarinderivatives HDACi An agent definitely possibly associate effect QT interval within 2 week screen Drugs induce inhibit CYP3A4 Pgp History : Clinically significant cardiac disease , symptomatic asymptomatic arrhythmia , syncopal episode , additional risk factor Torsades de pointes ( e.g . heart failure ) Malignancy transplantation , include skin cancer Kaposi sarcoma Diabetes mellitus Receipt strong immunosuppressive systemic chemotherapeutic agent within 28 day prior study entry Known resistance &gt; 2 class ART Known hypersensitivity component romidepsin , 3BNC117 analogue Women pregnant breastfeeding , positive pregnancy test screen Women Child Bearing Potential ( WOCBP ) unwilling unable use acceptable method nonestrogen contain contraception ( accord Danish Medicines Agency guideline ) avoid pregnancy 3 week study period 4 week study treatment undetectable plasma HIV1 RNA use standard assay Males female unwilling unable use barrier contraception sexual intercourse 3week study period , 4 week study treatment undetectable plasma HIV1 RNA use standard assay</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Latency Reversal Agent</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>